Our mission is to revolutionize precision oncology drug discovery and development by leveraging our Pointillist Platform which identifies tumor-specific cell surface epitopes, enabling us to develop life-changing medicines for cancer patients. Our founders are pioneers in cancer biology and our team has experience and success discovering, developing and commercializing oncology products.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
04/06/26	$100,000,000	Series A	Andreessen Horowitz Emerson Collective GordonMD Global Investments GV LoLa Capital Partners Nextech Invest RA Capital Management	undisclosed